According to the APBMT Activity Survey results, the number of HSCT has increased steadily in most of the APBMT countries. The number of HSCT performed until 2007 was 84,967. Approximately 50% of the HSCT recipients become long-term survivors, thus, the estimated number of long-term survivors exceed 40,000 in the APBMT countries / region.
Long-term survivors without relapse of underlying disease could suffer from various late complications after HSCT, such as chronic GVHD, infection, organ dysfunction, skeletal and muscular problems, endocrine complications, gonadal dysfunctions, secondary malignancy, growth problems, and quality of life issues. It will be beneficial to study differences in the follow-up clinical practice, the incidence and risk factors of these late complications among the APBMT countries / regions.
Minutes of the Late Effects Working Group Meetings are available here
Click on the following links to download.
Note: Access to the document links within the Minutes pages is restricted to members only and requires a password.
Chairman: Shinichiro Okamoto (Japan)
|Shinichiro Okamoto||Japan||Keio University|
|Yoshiko Atsuta||Japan||Nagoya University|
|Tahir Shamsi||Pakistan||National Institute of Blood Disease & Bone Marrow Transplantation|
|Micky Koh||Singapore||Deputy Director, Center of Transfusion Medicine Health Sciences Authority, Head-Bone Marrow Transplantation St George's Hospital and Medical School|
|David Ma||Australia||St Vincent's Hospital Sydney|
|Hoon Kook||Korea||Chonnam National University|
|Jong Wook Lee||Korea||Catholic University of Korea|
|Lin Kai-Hsin||Taiwan||National Taiwan University Hospital|
|Navin Khattry||India||Tata memorial hospital|
|Philip Rowlings||Australia||Calvary Mater Newcastle & HAPS|
|William YK Hwang||Singapore||Singapore General Hospital|